Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PRAX
stocks logo

PRAX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
59.44K
-80.32%
-3.093
+5.21%
--
--
-3.306
+0.47%
--
--
-3.414
+3.16%
Estimates Revision
The market is revising Downward the revenue expectations for Praxis Precision Medicines, Inc. (PRAX) for FY2025, with the revenue forecasts being adjusted by -29.66% over the past three months. During the same period, the stock price has changed by 508.56%.
Revenue Estimates for FY2025
Revise Downward
down Image
-29.66%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-2.55%
In Past 3 Month
Stock Price
Go Up
up Image
+508.56%
In Past 3 Month
Wall Street analysts forecast PRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRAX is 327.08 USD with a low forecast of 250.00 USD and a high forecast of 540.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast PRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRAX is 327.08 USD with a low forecast of 250.00 USD and a high forecast of 540.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 247.990
sliders
Low
250.00
Averages
327.08
High
540.00
Current: 247.990
sliders
Low
250.00
Averages
327.08
High
540.00
BTIG
NULL -> Buy
upgrade
$424 -> $499
2025-12-05
New
Reason
BTIG
Price Target
$424 -> $499
2025-12-05
New
upgrade
NULL -> Buy
Reason
BTIG raised the firm's price target on Praxis Precision to $499 from $424 and keeps a Buy rating on the shares. The firm also names the stock its Top Pick for 2026. The positive pre-NDA meeting and receipt of written feedback from the FDA aligns Praxis with the Agency on the content of its NDA for ulixa in ET that will be submitted in early 2026, the analyst tells investors in a research note.
Wedbush
Underperform
maintain
$77 -> $83
2025-12-05
New
Reason
Wedbush
Price Target
$77 -> $83
2025-12-05
New
maintain
Underperform
Reason
Wedbush raised the firm's price target on Praxis Precision to $83 from $77 and keeps an Underperform rating on the shares. The firm notes the company completed its pre-NDA meeting with FDA for ulixacaltamide. Most notable, Praxis will submit its ulixacaltamide NDA in early-2026. This is consistent with Wedbush expectations as its areas of concern are all issues that would be handled in review vs. a pre-NDA meeting.
Deutsche Bank
Buy
maintain
$270 -> $303
2025-12-05
New
Reason
Deutsche Bank
Price Target
$270 -> $303
2025-12-05
New
maintain
Buy
Reason
Deutsche Bank raised the firm's price target on Praxis Precision to $303 from $270 and keeps a Buy rating on the shares. The company announced a "double whammy of positive news," the analyst tells investors in a research note.
H.C. Wainwright
H.C. Wainwright
Buy
upgrade
$258 -> $340
2025-12-05
New
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$258 -> $340
2025-12-05
New
upgrade
Buy
Reason
H.C. Wainwright raised the firm's price target on Praxis Precision to $340 from $258 and keeps a Buy rating on the shares. The firm says relutrigine hit a "home run" in the EMBOLD study. H.C. Wainwright increased the probability of success for relutrigine to 80% from 60% and raised its projected peak sales to $2.8B from $760M.
BTIG
NULL
to
Buy
initiated
$424
2025-11-18
Reason
BTIG
Price Target
$424
2025-11-18
initiated
NULL
to
Buy
Reason
BTIG initiated coverage of Praxis Precision with a Buy rating and $424 price target. The firm, which sees a greater than $5B greenfield opportunity for ulixacaltamide in essential tremor, also notes that Praxis also has a pair of sodium channel modulators, vormatrigine and relutrigine, with positive Phase 2 data in epilepsy and developmental and epileptic encephalopathy, respectively.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$232 -> $258
2025-11-13
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$232 -> $258
2025-11-13
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Praxis Precision to $258 from $232 and keeps a Buy rating on the shares after meeting with management. The firm believes Praxis is "poised for nether breakout" with the relutrigine readout nearing. Management offered details that should ease an investor concerns regarding the interim readout for EMBOLD Cohort 2 which should bring relutrigine to market in 2026, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Praxis Precision Medicines Inc (PRAX.O) is -18.34, compared to its 5-year average forward P/E of -4.62. For a more detailed relative valuation and DCF analysis to assess Praxis Precision Medicines Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.62
Current PE
-18.34
Overvalued PE
-0.38
Undervalued PE
-8.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.01
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.92
Undervalued EV/EBITDA
-6.95

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
553.76
Current PS
0.00
Overvalued PS
1657.63
Undervalued PS
-550.12
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 587.88% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 587.88% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

PRAX News & Events

Events Timeline

(ET)
2025-12-05
16:20:00
S&P 500 Rises for Fourth Straight Day as Investors Anticipate Fed Rate Cut
select
2025-12-05
12:20:00
S&P 500 Rises for Fourth Straight Day as Investors Anticipate Fed Rate Cut
select
2025-12-05
12:10:00
Praxis Precision Stock Rises 34.7% to $255.83
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
02:10 AMBenzinga
PinnedPraxis' Epilepsy Medication Considered Too Effective to Proceed, FDA Meeting Scheduled Soon

  • Stock Performance: Praxis Precision Medicines Inc's stock rose 30.84% to $248.56 after positive results from the EMBOLD study on relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies, leading to an early recommendation to stop the study for efficacy.

  • FDA Meeting and NDA Timeline: The FDA has scheduled a meeting to review the EMBOLD data, after which Praxis will decide on the timing for filing a New Drug Application (NDA) for relutrigine, expected to be submitted in early 2026.

  • Analyst Outlook: Analysts from HC Wainwright have increased the probability of relutrigine's success to 80% and raised projected peak sales to $2.8 billion, while maintaining a Buy rating and increasing the price forecast for Praxis from $258 to $340.

  • Pipeline Developments: Praxis also reported positive results from its Phase 2 RADIANT study on vormatrigine, showing significant seizure reduction in patients with focal onset seizures and generalized epilepsy, contributing to the company's strong pipeline momentum.

[object Object]
Preview
9.0
12-05NASDAQ.COM
PinnedPraxis Precision Rises Following Encouraging Interim Results from EMBOLD Trial

  • Stock Performance: Praxis Precision Medicines, Inc. (PRAX) shares surged over 20% to $234.00 in premarket trading following a recommendation from the Data Monitoring Committee to halt the EMBOLD study of Relutrigine due to positive interim efficacy results.

  • Study Details: The EMBOLD study is a phase II trial focusing on Relutrigine for patients with early onset SCN2A-developmental epileptic encephalopathy (DEE) and SCN8A-DEE, which has shown a favorable safety profile and significant improvements in seizure control.

  • Upcoming Announcements: The company plans to present topline results from the EMBOLD study at the American Epilepsy Society Annual Meeting on December 6, 2025, and will meet with the FDA to discuss the data and potential next steps.

  • Historical Context: PRAX's stock was trading at approximately $41 when it was first highlighted on June 4, 2025, and has since seen a significant increase, closing at $189.97 before the recent premarket rise.

[object Object]
Preview
9.0
03:12 AMNewsfilter
Praxis Precision Stock Rallies on Positive EMBOLD Results and FDA Meeting Confirmation
  • Positive EMBOLD Results: Praxis Precision's announcement of favorable EMBOLD trial results exceeded expectations, driving stock price increases and showcasing its potential in the treatment landscape, which may lead to greater market recognition for the company.
  • FDA Meeting Confirmation: The confirmation of a meeting with the FDA further bolsters investor confidence in the product's market entry, with expectations of an expedited approval process that could shorten the time to market.
  • Analyst Expectations Raised: Analysts have increased their probability of success and peak sales forecasts, indicating a bullish sentiment regarding the company's future financial performance, which may attract more investor interest.
  • Positive Market Reaction: The stock price rally reflects market approval of the company's strategic direction, potentially paving the way for future financing and partnership opportunities, thereby enhancing its competitiveness in the biopharmaceutical sector.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Praxis Precision Medicines Inc (PRAX) stock price today?

The current price of PRAX is 247.99 USD — it has increased 30.54 % in the last trading day.

arrow icon

What is Praxis Precision Medicines Inc (PRAX)'s business?

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.

arrow icon

What is the price predicton of PRAX Stock?

Wall Street analysts forecast PRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRAX is 327.08 USD with a low forecast of 250.00 USD and a high forecast of 540.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Praxis Precision Medicines Inc (PRAX)'s revenue for the last quarter?

Praxis Precision Medicines Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Praxis Precision Medicines Inc (PRAX)'s earnings per share (EPS) for the last quarter?

Praxis Precision Medicines Inc. EPS for the last quarter amounts to -3.36 USD, increased 22.18 % YoY.

arrow icon

What changes have occurred in the market's expectations for Praxis Precision Medicines Inc (PRAX)'s fundamentals?

The market is revising Downward the revenue expectations for Praxis Precision Medicines, Inc. (PRAX) for FY2025, with the revenue forecasts being adjusted by -29.66% over the past three months. During the same period, the stock price has changed by 508.56%.
arrow icon

How many employees does Praxis Precision Medicines Inc (PRAX). have?

Praxis Precision Medicines Inc (PRAX) has 116 emplpoyees as of December 06 2025.

arrow icon

What is Praxis Precision Medicines Inc (PRAX) market cap?

Today PRAX has the market capitalization of 6.21B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free